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Abstract
Purpose We aim to provide an overview of the conventional single photon emission computed tomography (SPECT) and 
emerging positron emission tomography (PET) catecholamine analogue tracers for assessing myocardial nerve integrity, in 
particular focusing on 18F-labeled tracers.
Results Increasingly, the cardiac sympathetic nervous system (SNS) is being studied by non-invasive molecular imaging 
approaches. Forming the backbone of myocardial SNS imaging, the norepinephrine (NE) transporter at the sympathetic nerve 
terminal plays a crucial role for visualizing denervated myocardium: in particular, the single-photon-emitting NE analogue 
123I-meta-Iodobenzylguanidine (123I-mIBG) has demonstrated favorable results in the identification of patients at a high 
risk for cardiac death. However, cardiac neuronal PET agents offer several advantages including improved spatio-temporal 
resolution and intrinsic quantifiability. Compared to their 11C-labeled counterparts with a short half-life (20.4 min), novel 
18F-labeled PET imaging agents to assess myocardial nerve integrity have the potential to revolutionize the field of SNS 
molecular imaging. The longer half-life of 18F (109.8 min) allows for more flexibility in the study design and delivery from 
central cyclotron facilities to smaller hospitals may lead to further cost reduction. A great deal of progress has been made by 
the first in-human studies of such 18F-labeled SNS imaging agents. Moreover, dedicated animal platforms open avenues for 
further insights into the handling of radiolabeled catecholamine analogues at the sympathetic nerve terminal.
Conclusions 18F-labeled imaging agents demonstrate key properties for mapping cardiac sympathetic nerve integrity and 
might outperform current SPECT-based or 11C-labeled tracers in the long run.
Keywords 18F-LMI1195 · 11C-hydroxyephedrine · 123I-metaiodobenzylguanidine · Positron emission tomography · Single 
photon emission computed tomography · Sympathetic nerve
Introduction
Heart failure (HF) is primarily characterized by a vicious 
cycle: myocardial injury leads to reduced cardiac output, 
which triggers myocardial sympathetic nervous system 
(SNS) hyperactivity, which in turn leads to further cardiac 
damage and ultimately to a further reduction of systolic 
function [1, 2]. On a subcellular level, alterations of the 
myocardial SNS are manifest as an elevated plasma con-
centration of NE, an impaired function of NE transporter 
(uptake-1 mechanism) as well as by a reduced plasma clear-
ance of NE in the synaptic cleft [3, 4]. This phenomenon 
of “cardiac NE spillover” causes severe damage to cardiac 
myocytes via cyclic AMP-mediated calcium overloads, 
which result in a decrease of synthetic activity and viability 
[5]. Apart from that, a continuous oversupply of NE at the 
sympathetic nerve terminal triggers remodeling of the left 
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ventricle and the development of hypertensive left ventricu-
lar hypertrophy [6]. Not surprisingly, those insights into HF 
pathophysiology paved the way for a therapeutic approach 
via sympathetic inhibition: the CIBIS-II trial demonstrated 
a decreased cardiac mortality rate in HF patients undergo-
ing treatment with adrenergic beta blockers [7]. Of note, 
an incremental cost effectiveness ratio compared to other 
conventional cardiovascular treatments was documented [8]. 
On the contrary, the investigators of the “Sustained-release 
moxonidine in patients with HF (MOXCON)” trial exam-
ined the beneficial role of generalized sympathetic inhibition 
in HF using the imidazoline receptor agonist moxonidine 
and an increase in death rate led to early termination of this 
promising approach in HF treatment [9]. Taken together, the 
delicate balance of risk and benefit of therapeutic interven-
tions of cardiac sympathetic nerve blockade emphasizes the 
pivotal role of non-invasive imaging to assess the current 
status of the cardiac SNS. Moreover, such imaging concepts 
could potentially be applied to stratify one’s individual risk 
for sudden cardiac death or to determine the appropriate 
time-point at which to initiate further treatment for pro-
gressive HF. However, in contradistinction to conventional 
imaging modalities, molecular imaging using either single 
photon emission computed tomography (SPECT) or posi-
tron-emission tomography (PET) offers the unique oppor-
tunity to characterize alterations on a subcellular level and 
to gain deeper insights into cardiac disease development and 
early onset of HF [10]: Physiologic NE is stored in presyn-
aptic vesicles and once a firing impulse has arrived at the 
nerve terminal, NE is exocitotically released into the syn-
aptic cleft, where it is readily available for interacting with 
postsynaptic adrenoreceptors. After completing its primary 
task at the post-synapse, NE undergoes a recycling mecha-
nism via the presynaptic NE transporter (uptake-1) and is 
stored in vesicles for potential re-use [10–12]. Comparable 
to its physiologic counterpart, radiolabeled NE analogues 
are taken up into the nerve terminals using the identical 
uptake-1 pathway and, therefore, impaired cardiac NE func-
tion is reflected by either decreased radiotracer uptake or 
increased tracer washout. Figure 1 summarizes commonly 
used catecholamine analogue tracers to assess cardiac sym-
pathetic nerve integrity. In this review, we will discuss these 
radiolabeled SPECT and PET imaging agents for mapping 
the cardiac SNS, in particular focusing on recently intro-
duced 18F-labeled PET imaging probes.
Myocardial SNS imaging using SPECT
123I‑meta‑iodobenzylguanidine (123I‑mIBG) for risk 
stratification of HF‑related events
As a conventional scintigraphic approach, 123I-mIBG is a 
United States Food and Drug Administration-approved agent 
Fig. 1  Chemical structures of 
radiolabeled catecholamine 
analogue tracers in comparison 
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that has found widespread use in Japan, the United States, 
and Europe [13, 14]. Its prognostic role can be derived by 
calculating a heart-to-mediastinum ratio (HMR) obtained 
from planar scans, which can be considered as a semi-quan-
titative method to determine myocardial catecholamine 
uptake: patients below a certain HMR threshold are at a 
higher risk to experience cardiac events [15]. In a meta-
analysis, Verberne et al. included 18 studies with a total of 
1755 patients and concluded that decreased late HMR or 
increased myocardial 123I-mIBG washout are associated with 
a worse outcome compared to those patients without altera-
tions in semi-quantitatively derived 123I-mIBG parameters 
[16]. These findings were further confirmed by the prospec-
tive “AdreView Myocardial Imaging for Risk Evaluation in 
Heart Failure (ADMIRE-HF)” trial, which emphasized the 
potential benefit of 123I-mIBG imaging for risk stratification 
in patients suffering from severe HF. A highly significant 
association between time of HF-related events and the HMR 
was derived, independent of other common clinical param-
eters, such as left ventricular ejection fraction (LVEF) or 
renal function [17]. In a similar vein, Nakajima et al. cre-
ated dedicated mortality risk charts with 123I-mIBG imaging 
and clinical parameters (New York Heart Association Class 
(NYHA), Age, LVEF) with 2- and 5-year mortality risk esti-
mations that aimed to provide a more flexible platform for 
short- and long-term therapeutic decision-making in patients 
suffering from congestive HF [18].
123I‑mIBG as a risk stratification tool for potential 
device therapy candidates
Apart from risk stratification for HF-related cardiac events, 
the amount of denervated myocardium as assessed by 
123I-mIBG is being increasingly utilized to guide the refer-
ring treating cardiologist in regards to what time to initi-
ate further treatment, in particular by implantation of car-
dioverter defibrillators (ICD). ICD shocks for ventricular 
tachyarrhythmias are of utmost importance for secondary 
prevention of sudden cardiac death. Although the docu-
mented shock frequency varies among different studies 
[19], a considerable proportion of patients receive an inap-
propriate shock, in particular with single-chamber devices 
[20]. Apart from this risk of malfunction, up to 65% never 
have an appropriate ICD discharge after ICD implantation 
[21]. A recent published post hoc analysis performed by 
Verschure et al. demonstrated that the combination of late 
HMR and LVEF was associated with freedom of appro-
priate ICD therapy: consequently, it was concluded that 
123I-mIBG scintigraphy might be helpful in excluding those 
patients who might not benefit from ICD implantation [22]. 
A combination of 123I-mIBG and the “Seattle Heart Fail-
ure Model” using demographic as well as clinical mark-
ers improved risk stratification in high-risk HF patients for 
potential therapeutic assessment with ICD or cardiac resyn-
chronization therapy (CRT) [23]. The latter therapeutic 
approach has proven to be highly effective in patients with 
complete left bundle branch block, but an extensive body of 
literature demonstrated that a significant number of patients 
receiving CRT have to deal with device complications [24]. 
Thus, analogous to ICD therapy, 123I-mIBG imaging might 
meet this urgent clinical need of selecting appropriate can-
didates for CRT initiation. Utilizing a baseline 123I-mIBG 
scan, Nishioka et al. demonstrated that lower HMR could 
identify CRT non-responders [25]. The currently recruiting, 
event-driven Phase IIIb multicenter, randomized, prospec-
tive “International Study to Determine if AdreView Heart 
Function Scan Can be Used to Identify Patients With Mild or 
Moderate Heart Failure (HF) That Benefit From Implanted 
Medical Device (ADMIRE-ICD)” trial may provide further 
insights into the efficacy of 123I-mIBG for selecting patients 
who most likely benefit from ICD implantation [26]. Taken 
together, these data suggest that 123I-mIBG can be used to 
guide the treating cardiologist to identify high-risk patients 
who benefit from device therapy. Thus, one might speculate 
that the non-invasive assessment of myocardial nerve integ-
rity using 123I-mIBG has the potential to outperform cur-
rent selection criteria, such as LVEF or electrocardiogram-
derived QRS duration [13, 27].
123I‑mIBG for other clinical scenarios
Scintigraphic assessment of the SNS of the heart might be 
also helpful in heart-transplant recipients, as sympathetic 
reinnervation could successfully be monitored by 123I-mIBG 
up to 1 year after operation [28]. Thus, 123I-mIBG could have 
utility in selecting appropriate transplantation candidates or 
might contribute to further determining expected post-sur-
gical survival rates [13]. Gerson et al. studied 343 diabetic 
and 618 nondiabetic subjects with NYHA class II or III HF 
and the combination of diabetes mellitus and HMR predicted 
HF progression independently. Thus, diabetic patients with 
impaired SNS function of the heart seem to be at higher risk 
and consequently, lifestyle changes could be further pro-
moted or anti-diabetic treatment could be intensified among 
those individuals [29]. Apart from that, Sobajima et al. dem-
onstrated immediate improvement of SNS activity (assessed 
by 123I-mIBG washout rate) after transcatheter aortic valve 
implantation (TAVI) in patients suffering from aortic valve 
stenosis. Hence, 123I-mIBG might serve as a risk stratifica-
tion tool or could also monitor the therapeutic efficacy of 
TAVI [30]. Moreover, 123I-mIBG imaging has also been used 
to evaluate cardiac involvement in multiorgan diseases: On 
a small cohort of 5 patients, Yamamoto et al. demonstrated 
that cardiac sympathetic nerve activity is reduced in sub-
jects diagnosed with Anderson-Fabry Disease (AFD) [31]. 
These preliminary findings were further corroborated on a 
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larger scale in 25 patients with genetically proven AFD: in 
a comparison of 123I-mIBG and cardiac magnetic resonance 
imaging, impaired sympathetic nerve function preceded 
myocardial structural damage, such as fibrosis [32]. Apart 
from that, 123I-mIBG is also considered as a valuable risk 
stratification tool in non-cardiac diseases, such as neuro-
generative disorders: it has been proven that HMR based on 
123I-mIBG scintigraphy can differentiate between Dementia 
with Lewy Bodies and Alzheimer disease even in patients 
without parkinsonism [33].
PET imaging agents for myocardial SNS 
assessment—11C‑labeled tracers
Despite its potential incremental value over conventional 
clinical parameters, 123I-mIBG suffers from several draw-
backs. HMR is a global marker of cardiac nerve integrity, 
and thus it does not provide any further details of regional 
heterogeneity of denervated myocardium in viable border 
zones [10, 34]. However, cardiac neuronal PET imaging 
agents offer several advantages over 123I-mIBG SPECT 
including improved spatio-temporal resolution and quan-
tification approaches [35]. Hence, in contradistinction to 
a global assessment of the cardiac nerve integrity using 
123I-mIBG-derived HMR, PET-based assessment of dener-
vated myocardium opens avenues for regional analysis of 
different myocardial areas simultaneously (e.g., infarct zone, 
border zone or remote myocardium) [10].
Several 11C-labeled catecholamine analogue radiotracers 
have been investigated to assess myocardial SNS: The three 
most commonly used radiotracers are 11C-hydroxyephedrine 
(11C-HED), 11C-epinephrine and 11C-phenylepinephrine [12, 
35]. All of these carbon-11 compounds differ in their kinetic 
properties, such as their affinity for neuronal uptake-1 as 
well as susceptibility to degrading enzymes, e.g. monoam-
ine oxidase (MAO) and catechol-O-methyltransferase [36]. 
Hence, a combination of multiple PET radiotracers with 
such distinct differences in their properties may offer more 
profound insight into cardiac sympathetic neurotransmis-
sion in the failing heart [10, 35]: in an 11C-labeled triple-
radiotracer approach in otherwise healthy heart-transplant 
recipients, different underlying characteristics in catecho-
lamine handling after cardiac transplantation was demon-
strated [37].
In clinical trials and daily clinical routine, 11C-HED is 
the most widely used PET radiotracer to assess sympathetic 
nerve conditions: in a recent study, a low global 11C-HED 
retention was linked to poorer overall survival in patients 
with LV dysfunction [38]. Analogous to its scintigraphy-
based counterpart (ADMIRE-HF) [17], the prospective 
“Prediction of ARrhythmic Events with Positron Emission 
Tomography (PAREPET)” trial proved that the volume of 
denervated myocardium is a strong predictor of sudden car-
diac arrest, independent of other clinical parameters, such 
as LVEF, infarct volume or hybernating myocardium. Quan-
titatively, each 1% increase in the denervated myocardial 
volume was associated with a 5.7% increase in sudden car-
diac arrest. Hence, this PET-driven imaging assessment of 
myocardial sympathetic denervation could also be helpful 
in differentiating between low- and high-risk patients who 
most likely benefit from ICD implantation [39]. As a com-
mon comorbidity in chronic heart disease [40], Hall et al. 
investigated the beneficial use of 11C-HED in HF patients 
suffering from obstructive sleep apnea (OSA) under con-
tinuous positive airway pressure (cPAP) therapy. Of note, 
short-term cPAP therapy of 6–8 weeks increased 11C-HED 
retention and, therefore, indicated an improved myocardial 
SNS. This might pave the way to link potential alterations 
in 11C-HED retention indices to clinical outcome in patients 
suffering from OSA [41].
Novel cardiac neuronal PET imaging agents: 
18F‑labeled radiotracers
11C-labeled radiotracers are currently the most frequently 
used cardiac PET imaging agents for mapping sympathetic 
nerve conditions of the heart. However, higher expenses 
for purchase, maintenance of costly on-site cyclotrons, and 
the necessity of staff to prepare such radiopharmaceuticals 
increases the financial burden for both patients as well as 
for primary or secondary care hospitals. The financial bur-
den for radiotracer production is a consideration for practi-
tioners as to what extent 11C-HED should be employed in 
daily clinical routine [26]. On the other hand, 18F-labeled 
radiotracers have a significantly longer half-life (110 min) 
and might overcome these hurdles. First, the longer half-
life allows for delivery from central cyclotron facilities to 
smaller hospitals with stand-alone PETs, which has proven 
to be cost-effective for the commonly used oncology 
imaging agent 2-deoxy-2-18F-fluoro-d-glucose [42]. Such 
18F-labeled cardiac neuronal imaging agents could even 
be distributed by commercial vendors [43]. Second, the 
longer half-life would also allow for flexibility in the study 
protocol, e.g. by facilitating the acquisition of both early 
and delayed time point imaging analogous to 123I-mIBG. 
Moreover, fluoride introduction into PET agents increases 
the stability of a radiopharmaceutical, as the risk of metabo-
lism at sensitive positions is reduced [44]. Consequently, 
18F-labeled radiotracers can help realize the full potential 
of PET imaging technology and, therefore, novel cardiac 
SNS imaging agents have recently been introduced, includ-
ing 18F-LMI1195 as well as 18F-Fluoro-Hydroxypheneth-
ylguanidines  [18F-fluoro-3-hydroxyphenethylguanidine 
( 1 8F - 4 F - M P H G )  a n d  i t s  s t r u c t u r a l  i s o m e r 





Sharing a benzylguanidine structure similar to its SPECT 
counterpart 123I-mIBG, 18F-LMI1195 is not subject to fur-
ther metabolism by enzymes such as MAO. As a major 
advantage, it can be easily obtained by a simple one-step 
18F replacement reaction [44].
Using a cell membrane-binding assay, it was demon-
strated that 18F-LMI1195 is taken up via uptake-1 mecha-
nism into the presynaptic nerve terminal. Moreover, in an 
in vitro blocking study using the potent uptake-1 block-
ing agent desipramine (DMI), the high specificity of 18F-
LMI1195 to uptake-1 was further corroborated [45]. Uti-
lizing isolated perfused rabbit hearts to avoid systemic 
recirculation and metabolism of the radiotracer, a flow-
dependent decrease of the first-pass radiotracer extraction 
fraction was demonstrated: therefore, one might speculate 
that the initial uptake depends on the radiotracer quantity in 
the extracellular spaces which is limited by blood flow [46]. 
However, Yu et al. examined a denervated rabbit model and 
after an initial uptake in the first 2 min in both innervated 
and denervated areas, 18F-LMI1195 was rapidly washed out 
thereafter [47].
After being taken up into presynaptic nerve terminals via 
uptake-1, it was questioned whether 18F-LMI1195 is stored 
in presynaptic vesicles [10]. Therefore, in an in vivo head-
to-head comparison using healthy rabbits, the most com-
monly used SPECT/PET catecholamine analogue radiotrac-
ers (123I-mIBG, 11C-HED) and 18F-LMI1195 were studied 
by our research group: all of these tracers could be blocked 
by pretreatment with the potent uptake-1 blocker DMI 
before tracer injection. Similar findings of a selective NET 
inhibitor blockage via DMI has been previously reported 
for both 123I-mIBG and 18F-LMI1195 in the rabbit heart 
[45]. However, distinct radiotracer properties were revealed 
using a DMI chase protocol (i.e., DMI administered after 
tracer delivery): retention kinetics of the benzylguanidine-
based tracers 123I-mIBG and 18F-LMI1195 remained stable, 
while 11C-HED washout increased significantly. Integrating 
these data, it can be hypothesized that 123I-mIBG and 18F-
LMI1195 are stably stored in presynaptic vesicles (resistant 
to NET inhibitor chase) and, therefore, mimic physiologi-
cal NE turnover. On the contrary, 11C-HED undergoes a 
continuous cycle of NET uptake and release at the nerve 
terminal (Fig. 2) [35]. These findings were further corrobo-
rated by electric field stimulation in isolated perfused rab-
bit hearts: this approach lead to increased washout rate of 
18F-LMI1195, as it provoques vesicular NE release [46]. Of 
note, all of those studies were conducted using rabbit myo-
cardium: similar to the human heart, the contribution of NE 
clearance to neuronal uptake-1 is also pronounced in rabbits 
and, therefore, the rabbit heart serves as a suitable platform 
to mimic human cardiac nerve status [48, 49]. However, our 
research group also recently investigated (vesicle-poor) SK-
N-SH cells vs. (vesicle-rich) PC12 cells in combination with 
18F-LMI1195 and we found that stimulants for storage vesi-
cle turnover (reserpine, high potassium chloride) enhanced 
18F-LMI1195 washout from PC12 cells, while radiotracer 
retention remained stable in SK-N-SH cells [50].
Multiple studies have reported on the high specificity 
of 18F-LMI1195 for uptake-1 in different species, such as 
monkeys. A clear delineation of the myocardium was visual-
ized with a significantly higher heart-to-background ratio, 
mainly due to a rapid washout from the lung and liver as well 
as a quick radiotracer clearance from the blood. Compared 
to 123I-mIBG, a three-fold higher heart-to-liver ratio could 
be derived for 18F-LMI1195 in cynomonkeys [45]. How-
ever, species- and radiotracer-dependent variations among 
different cardiac catecholamine analogue tracers have to 
be taken into account. For example in Wistar rats, cardiac 
uptake of 18F-LMI1195 was significantly altered using the 
NE uptake-2 inhibitor phenoxybenzamine (but not by the 
uptake-1 blocker DMI). Thus, in contradistinction to other 
species, 18F-LMI1195 is primarily a substrate of uptake-2 in 
rats [51]. However, 11C-HED can be successfully inhibited 
by the uptake-1 blocker DMI in rat hearts and, therefore, 
11C-HED uptake has a high affinity to neuronal uptake-1 
in that species. Of note, this does not apply to 123I-mIBG: 
analogous to 18F-LMI1195, 123I/131I-mIBG demonstrated 
distinct characteristics of uptake mechanism that are com-
patible with a significant contribution from nonneuronal 
uptake-2 in the rat heart [52]. The underlying chemical 
structure (benzylguanidine) might explain the similarities 
between mIBG and LMI1195 in the rat myocardium. Hence, 
to investigate catecholamine analogue radiotracer handling 
in the nerve terminal, the animal platform to test a particular 
SNS imaging agent has to be chosen with extreme caution 
[52]. 18F-LMI1195 might also allow for detection and quan-
tification of loco-regional areas of denervation. In dener-
vated rabbit myocardium, 18F-LMI1195 could differentiate 
between innervated vs. denervated areas, while the reference 
myocardial perfusion PET radiotracer 18F-flurpiridaz dem-
onstrated no abnormalities. Of note, 18F-LMI1195 was able 
to monitor reinnervation in previous denervated areas (2 vs. 
12 weeks post-denervation) [47].
Noteworthy, 18F-LMI1195 is the only 18F-labeled cat-
echolamine analogue radiotracer that has entered phase-1 
and phase-2 trials. Sinusas et al. reported on promising 
radiotracer characteristics with favorable biodistribution: 
over 5 h, stable myocardial activity, which was uniform 
throughout the myocardium, as well as rapid blood clear-
ance was demonstrated. Dynamic PET revealed excellent 
heart-to-lung and heart-to-liver ratios (Fig. 3). In the twelve 
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healthy volunteers, no adverse events or safety concerns 
were documented. Dosimetrically, the most critical organ 
was identified as the urinary bladder wall, followed by the 
kidneys. However, the mean effective dose was rather low 
and comparable to 123I-mIBG [53]. Of note, in a recently 
published head-to-head comparison of 18F-LMI1195 and 
11C-HED, preliminary assessment in 9 participants revealed 
comparable estimates of cardiac autonomic nervous func-
tion. However, compared to its 11C-based counterpart, the 
18F-labeled imaging agent demonstrated superior kinetics, in 
particular for early cardiac imaging [54]. Hence, this phase-2 
trial might pave the way for a phase-3 trial, which would 
further investigate the potential benefit of 18F-LMI1195 for 
risk stratification among HF patients.
18F‑fluoro‑hydroxyphenethylguanidines
Apart from 18F-LMI1195, two other 18F-labeled catechola-
mine analogue radiotracers have been introduced, namely 
18F-4F-MPHG and 18F-3F-PHPG. Both radiotracers were 
Fig. 2  a Averaged time activity 
curves and b representative 
short-axis images of in vivo 
rabbit cardiac PET imaging. 
Desipramine (DMI) chase (i.e., 
DMI administered after tracer 
delivery) enhanced 11C-Hydrox-
yephedrine (11C-HED) tracer 
washout, while 18F-LMI1195 
washout remained stable. 
c Results of in vivo rabbit 
123I-metaiodobenzylguanidine 
(123I-mIBG) planar scintigraphy 
of the chest. Similar to 18F-
LMI1195, DMI chase did not 
change cardiac distribution of 
123I-mIBG. This might be due to 
the underlying benzylguanidine 
structure shared by both radi-
otracers. Dotted lines indicate 
regions of interest in both heart 
and mediastinum. Modified 
from Werner et al. [35] © by the 
Society of Nuclear Medicine 
and Molecular Imaging, Inc.
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taken up more slowly and demonstrated significantly longer 
neuronal retention times compared to 11C-HED or 11C-mIBG 
in isolated rat hearts, mainly due to efficient storage inside 
NE storage vesicles [55]. Such key characteristics might be 
of utmost importance in kinetic analyses of regional nerve 
density assessment, as such radiotracers are capable of 
reflecting even modest alterations of cardiac sympathetic 
nerve conditions without being hampered by the blood flow 
effect. Common sympathetic nerve agents such as 11C-HED 
or 123I-mIBG are too rapidly taken up via uptake-1 to allow 
for reliable compartmental modeling of their kinetics. Thus, 
the neuronal uptake for 11C-HED by uptake-1 from extra-
cellular space (k3) is much faster than k2 (clearance from 
extracellular space back to plasma), i.e., k3 ≫ k2. Conse-
quently, 11C-HED retention measurements are not sensi-
tive to moderate loss in nerve integrity and rather limited 
to myocardial regions in which nerve losses are severe [43]. 
However, the phenethylguanidine-like structure of 18F-4F-
MPHG and 18F-3F-PHPG overcomes these hurdles as they 
offer the main advantage of slow neuronal uptake and long 
neuronal retention [55].
In-vivo imaging studies in monkeys further corroborated 
the favorable kinetic properties of both 18F-labeled radi-
otracers, as the myocardium could be clearly delineated. In 
an in vivo blocking study with varying amounts of DMI, 
retention indices of 18F-4F-MPHG decreased with increas-
ing levels of the uptake-1 blocking agent. The obtained 
“net uptake rate” constant, derived from compartmental 
modeling or Patlak analysis of 18F-4F-MPHG kinetics, also 
declined dose-dependently with increasing DMI doses [56]. 
Thus, these compounds seem to have optimal kinetics and 
can allow for quantitative assessment of even a slight loss 
of cardiac sympathetic nerve density or regional denerva-
tion [44].
18F-4F-MPHG and 18F-3F-PHPG have been tested in 
humans and both imaging agents demonstrated clear delin-
eation of the myocardium along with low liver and lung 
uptake. Kinetic analyses of both radiotracers using Patlak 
demonstrated encouraging results and regional mapping of 
cardiac nerve integrity in humans seems feasible [57].
Table 1 summarizes the herein presented SPECT and 
PET catecholamine analogue tracers to assess cardiac sym-
pathetic nerve conditions, along with several advantages and 
limitations of each agent.
Conclusions
In this review, we provided an overview of the most com-
monly used SPECT and PET catecholamine analogue radi-
otracers for mapping myocardial nerve integrity. 123I-mIBG 
is considered to be the “Work Horse” in daily clinical rou-
tine [13] and multiple studies have demonstrated its benefit 
in different clinical scenarios. The prospective ADMIRE-
HF trial showed its prognostic capability in identifying HF 
patients at risk, independent of other clinical parameters 
such as LVEF [17]. Moreover, the currently event-driven 
recruiting ADMIRE-ICD trial will determine the role of 
this imaging approach in selecting appropriate candidates 
for left-ventricular assistant device therapy [26]. However, 
123I-mIBG merely provides a global assessment of car-
diac nerve integrity, but novel innovative techniques such 
as Cadmium-zinc-telluride scanners may provide further 
information beyond available standard planar imaging tech-
niques [58]. In contradistinction to SPECT, neuronal PET 
imaging agents offer several advantages, such as improved 
spatio-temporal resolution or regional analysis of different 
myocardial areas [10]. Multiple 11C-labeled catecholamine 
analogue PET radiotracers have been investigated to assess 
myocardial SNS: in particular, the prospective PAREPET 
trial demonstrated a strong association between the volume 
of denervated myocardium assessed by 11C-HED and cardiac 
events [39]. Compared to their 11C-labeled counterparts, 
the longer half-life of 18F allows for delivery from central 
cyclotron facilities to smaller hospitals with stand-alone 
PET scanners and, consequently, such 18F-labeled cardiac 
imaging agents could even be distributed by commercial 
vendors. Thus, a costly on-site cyclotron is not needed 
and the financial burden for the healthcare system may be 
significantly reduced. Moreover, 18F-labeled radiotracers 
also allow for more flexibility in the study protocol, such 
as delayed imaging [44]. The 18F-labeled imaging agents 
included in this review (18F-LMI1195, 18F-4F-MPHG and 
18F-3F-PHPG) demonstrate excellent imaging quality and 
key properties such as reduced background uptake due to 
favorable heart-to-liver ratios, regional assessment of dif-
ferent myocardial areas, and/or kinetic behavior at the nerve 
Fig. 3  Representative sequences of whole-body 18F-LMI1195 images 
in healthy volunteers approximately 10 min, 1, 2 and 5 h post-injec-
tion. Modified from Sinusas et al. [53] © by the Society of Nuclear 
Medicine and Molecular Imaging, Inc.
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terminal similar to physiological NE [35, 57]. Encouraging 
results from a recently published phase-2 trial demonstrated 
that the kinetics of 18F-LMI1195 might be superior to 11C-
HED: this could pave the way for a phase-3 trial to evalu-
ate the potential role of 18F-LMI1195 for risk stratification 
among HF patients [54]. On the contrary, 18F-4F-MPHG and 
18F-3F-PHPG offer the advantage of slow neuronal uptake 
and long neuronal retention and, therefore, such radiotrac-
ers are capable of reflecting even modest alterations of car-
diac sympathetic nerve conditions by kinetic analyses [55]. 
Nonetheless, future studies should focus on the underlying 
mechanisms of these PET and SPECT agents, in particular 
to guide the clinical reader in interpreting imaging results 
or to combine multiple radiotracers with different kinetic 
properties to gain further insight into NE handling at the 
nerve terminal.
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Table 1  Head-to-head comparison of single-photon emission computed tomography (SPECT) vs. positron emission tomography (PET) agents 
for cardiac innervation imaging, along with several advantages and limitations
AdreView myocardial imaging for risk evaluation in heart failure (ADMIRE-HF), International Study to determine if AdreView heart func-
tion scan can be used to identify patients with mild or moderate heart failure (HF) that benefit from implanted medical device (ADMIRE-ICD), 
heart-to-mediastinum ratio (HMR), Prediction of ARrhythmic events with positron emission tomography (PAREPET)
123 I-mIBG 123I-meta-Iodobenzylguanidine, 11C-HED 11C-hydroxyephedrine, 18F-LMI1195 N-[3-Bromo-4-(3-[18F]fluoro-propoxy)-benzyl]-guan-
idine, 18F-4F-MPHG 18F-fluoro-3-hydroxyphenethylguanidine, 18F-3F-PHPG 3-18F-fluoro-4-hydroxyphenethylguanidine
Imaging Modality Catecholamine analogue tracer Advantages Limitations
SPECT 123I-mIBG Long-standing experience [13]
Food-and-drug administration approved 
[11]
Considered as the “work horse” [13, 26]
Clincially well-established HMR ratio 
[15]
Evidence from different prospective 
trials (ADMIRE-HF, ADMIRE-ICD) 
[17]
HMR as a global marker of cardiac nerve 
integrity [10]
No regional analysis of different myocar-
dial areas [10, 44]
HMR primarily obtained by planar 
images [15]
Cost-effectiveness data are lacking [13]
PET 11C-Hydroxyephedrine Higher spatio-temporal resolution [11]
Most widely used cardiac sympathetic 
nerve PET radiotracer [11]
Denervated myocardium as a strong 
predictor of sudden cardiac arrest 
(PAREPET trial) [39]
Quantitative assessment of different 
myocardial areas [44]
High financial burden [44]
Short half-life of 11C (20.4 min) limits the 
design of novel imaging agents [44]
Potential cold-mass effect of 11C [59]
Phase-2 study: superior kinetics of 18F-
LMI1195 compared to 11C-HED [54]
18F-LMI1195 Simple one-step 18F replacement reac-
tion [44]
First 18F-labeled radiotracer in a phase-1 
and -2 trial [53, 54]
Longer half-life (110 min): flexibility in 
the study protocol, higher flexibility in 
producing novel SNS cardiac imaging 
agents [11, 44]
Readily transported and stored into 
synaptic vesicles [35]
Phase 2 study: superior kinetics of 18F-
LMI1195 [54]
Limited to university hospitals/tertiary 
referral hospitals
No data available regarding potential 
benefit in risk stratification among HF 
patients
18F-Fluoro-Hydroxyphenethyl-guan-
idines (18F-4F-MPHG and 18F-3F-
PHPG)
Slow uptake and longer neuronal reten-
tion times: potential to reflect even 
modest alterations of cardiac sympa-
thetic nerve conditions [55]
Feasibility of compartmental modeling 
or Patlak analysis [55, 57]
First-in-human study: low liver and lung 
uptake [57]
Limited to university hospitals/tertiary 
referral hospitals
No data available regarding potential 
benefit in risk stratification among HF 
patients
301Clinical and Translational Imaging (2018) 6:293–303 
1 3
Author’s Contributions RAW: Literature search, Literature review, 
Writing, Editing, Content planning. XC: Literature search, Literature 
review. MH: Editing, Content planning, Other (Figures). SPR: Litera-
ture review, Writing, Editing. CL: Literature review, Writing, Editing. 
MSJ: Literature review, Writing, Editing, Content planning, Other (Pro-
ject Development). TH: Literature search, Literature review, Writing, 
Editing, Content planning, Other (Project Development).
Compliance with ethics guidelines 
Conflict of interest All authors (RAW, XC, MH, SPR, CL, MSJ, TH) 
declare that they do not have any conflict of interest.
Research involving human and animal participants The article contains 
data from studies with animal subjects performed by the authors of this 
article. All institutional and national guidelines for the care and use of 
laboratory animals were followed. All procedures performed in stud-
ies involving animals were in accordance with the ethical standards of 
the institution or practice at which the studies were conducted. This 
article does not contain any studies with human participants performed 
by any of the authors.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Zhang DY, Anderson AS (2014) The sympathetic nervous sys-
tem and heart failure. Cardiol Clin 32(1):33–45. https ://doi.
org/10.1016/j.ccl.2013.09.010
 2. Parati G, Esler M (2012) The human sympathetic nervous sys-
tem: its relevance in hypertension and heart failure. Eur Heart J 
33(9):1058–1066. https ://doi.org/10.1093/eurhe artj/ehs04 1
 3. Veith RC, Featherstone JA, Linares OA, Halter JB (1986) Age dif-
ferences in plasma norepinephrine kinetics in humans. J Gerontol 
41(3):319–324
 4. Liang CS (2007) Cardiac sympathetic nerve terminal function in 
congestive heart failure. Acta Pharmacol Sin 28(7):921–927. https 
://doi.org/10.1111/j.1745-7254.2007.00585 .x
 5. Mann DL, Kent RL, Parsons B, Gt Cooper (1992) Adrenergic 
effects on the biology of the adult mammalian cardiocyte. Circula-
tion 85(2):790–804
 6. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous 
F, Esler MD (2003) Relation between cardiac sympathetic activ-
ity and hypertensive left ventricular hypertrophy. Circulation 
108(5):560–565. https ://doi.org/10.1161/01.CIR.00000 81775 
.72651 .B6
 7. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a ran-
domised trial (1999) Lancet 353(9146):9–13
 8. Ekman M, Zethraeus N, Jonsson B (2001) Cost effectiveness of 
bisoprolol in the treatment of chronic congestive heart failure in 
Sweden: analysis using data from the Cardiac Insufficiency Biso-
prolol Study II trial. Pharmacoeconomics 19(9):901–916
 9. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub 
M, Wiltse C, Wright TJ, Investigators M (2003) Adverse mortal-
ity effect of central sympathetic inhibition with sustained-release 
moxonidine in patients with heart failure (MOXCON). Eur J Heart 
Fail 5(5):659–667
 10. Bengel FM (2011) Imaging targets of the sympathetic nervous 
system of the heart: translational considerations. J Nucl Med 
52(8):1167–1170. https ://doi.org/10.2967/jnume d.110.08422 8
 11. Thackeray JT, Bengel FM (2016) PET imaging of the autonomic 
nervous system. Q J Nucl Med Mol Imaging 60(4):362–382
 12. Chen X, Werner RA, Javadi MS, Maya Y, Decker M, Lapa C, 
Herrmann K, Higuchi T (2015) Radionuclide imaging of neuro-
hormonal system of the heart. Theranostics 5(6):545–558. https 
://doi.org/10.7150/thno.10900 
 13. Nakajima K, Nakata T (2015) Cardiac 123I-MIBG imaging 
for clinical decision making: 22-year experience in Japan. J 
Nucl Med 56(Suppl 4):11S–19S. https ://doi.org/10.2967/jnume 
d.114.14279 4
 14. Nakajima K, Scholte A, Nakata T, Dimitriu-Leen AC, Chika-
mori T, Vitola JV, Yoshinaga K (2017) Cardiac sympathetic 
nervous system imaging with (123)I-meta-iodobenzylguanidine: 
perspectives from Japan and Europe. J Nucl Cardiol 24(3):952–
960. https ://doi.org/10.1007/s1235 0-017-0818-y
 15. Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ 
(2016) ASNC imaging guidelines for SPECT nuclear cardiol-
ogy procedures: stress, protocols, and tracers. J Nucl Cardiol 
23(3):606–639. https ://doi.org/10.1007/s1235 0-015-0387-x
 16. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL 
(2008) Prognostic value of myocardial 123I-metaiodobenzyl-
guanidine (MIBG) parameters in patients with heart failure: a 
systematic review. Eur Heart J 29(9):1147–1159. https ://doi.
org/10.1093/eurhe artj/ehn11 3
 17. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, 
Lopez VA, Agostini D, Weiland F, Chandna H, Narula J, Inves-
tigators A-H (2010) Myocardial iodine-123 meta-iodobenzyl-
guanidine imaging and cardiac events in heart failure. Results of 
the prospective ADMIRE-HF (AdreView Myocardial Imaging 
for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 
55(20):2212–2221. https ://doi.org/10.1016/j.jacc.2010.01.014
 18. Nakajima K, Nakata T, Matsuo S, Jacobson AF (2016) Crea-
tion of mortality risk charts using 123I meta-iodobenzylguan-
idine heart-to-mediastinum ratio in patients with heart failure: 
2- and 5-year risk models. Eur Heart J Cardiovasc Imaging 
17(10):1138–1145. https ://doi.org/10.1093/ehjci /jev32 2
 19. Auricchio A, Schloss EJ, Kurita T, Meijer A, Gerritse B, Zwei-
bel S, AlSmadi FM, Leng CT, Sterns LD, PainFree SSTI (2015) 
Low inappropriate shock rates in patients with single- and dual/
triple-chamber implantable cardioverter-defibrillators using a 
novel suite of detection algorithms: PainFree SST trial primary 
results. Heart Rhythm 12(5):926–936. https ://doi.org/10.1016/j.
hrthm .2015.01.017
 20. Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Fer-
rer JB, Hersi A, Gulaj M, Wijfels MC, Santi E, Manotta L, 
Arenal A (2013) Effect of long-detection interval vs standard-
detection interval for implantable cardioverter-defibrillators on 
antitachycardia pacing and shock delivery: the ADVANCE III 
randomized clinical trial. JAMA 309(18):1903–1911. https ://
doi.org/10.1001/jama.2013.4598
 21. Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown 
MW, Daubert JP, McNitt S, Andrews ML, Elkin AD, Multi-
center Automatic Defibrillator Implantation Trial IIRG (2004) 
Long-term clinical course of patients after termination of ven-
tricular tachyarrhythmia by an implanted defibrillator. Circula-
tion 110(25):3760–3765. https ://doi.org/10.1161/01.CIR.00001 
50390 .04704 .B7
 22. Verschure DO, de Groot JR, Mirzaei S, Gheysens O, Nakajima 
K, van Eck-Smit BLF, Aernout Somsen G, Verberne HJ (2017) 
Cardiac (123)I-mIBG scintigraphy is associated with free-
dom of appropriate ICD therapy in stable chronic heart failure 
302 Clinical and Translational Imaging (2018) 6:293–303
1 3
patients. Int J Cardiol 248:403–408. https ://doi.org/10.1016/j.
ijcar d.2017.08.003
 23. Ketchum ES, Jacobson AF, Caldwell JH, Senior R, Cerqueira 
MD, Thomas GS, Agostini D, Narula J, Levy WC (2012) Selec-
tive improvement in Seattle Heart Failure Model risk stratifi-
cation using iodine-123 meta-iodobenzylguanidine imaging. J 
Nucl Cardiol 19(5):1007–1016. https ://doi.org/10.1007/s1235 
0-012-9603-0
 24. Strauss DG, Selvester RH, Wagner GS (2011) Defining left bun-
dle branch block in the era of cardiac resynchronization therapy. 
Am J Cardiol 107(6):927–934. https ://doi.org/10.1016/j.amjca 
rd.2010.11.010
 25. Nishioka SA, Martinelli Filho M, Brandao SC, Giorgi MC, Vieira 
ML, Costa R, Mathias W, Meneghetti JC (2007) Cardiac sympa-
thetic activity pre and post resynchronization therapy evaluated by 
123I-MIBG myocardial scintigraphy. J Nucl Cardiol 14(6):852–
859. https ://doi.org/10.1016/j.nuclc ard.2007.08.004
 26. Travin MI (2017) Current clinical applications and next steps for 
cardiac innervation imaging. Curr Cardiol Rep 19(1):1. https ://
doi.org/10.1007/s1188 6-017-0817-2
 27. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, 
Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, 
Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont 
L, Padeletti L, Sutton R, Vardas PE, Zamorano JL, Achenbach 
S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol 
C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knu-
uti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Pie-
poli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, 
Torbicki A, Wijns W, Windecker S, Document R, Kirchhof P, 
Blomstrom-Lundqvist C, Badano LP, Aliyev F, Bansch D, Baum-
gartner H, Bsata W, Buser P, Charron P, Daubert JC, Dobreanu 
D, Faerestrand S, Hasdai D, Hoes AW, Le Heuzey JY, Mavrakis 
H, McDonagh T, Merino JL, Nawar MM, Nielsen JC, Pieske B, 
Poposka L, Ruschitzka F, Tendera M, Van Gelder IC, Wilson 
CM, Guidelines ESCCFP (2013) 2013 ESC Guidelines on cardiac 
pacing and cardiac resynchronization therapy: the Task Force on 
cardiac pacing and resynchronization therapy of the European 
Society of Cardiology (ESC). Developed in collaboration with 
the European Heart Rhythm Association (EHRA). Eur Heart J 
34(29):2281–2329. https ://doi.org/10.1093/eurhe artj/eht15 0
 28. De Marco T, Dae M, Yuen-Green MS, Kumar S, Sudhir K, 
Keith F, Amidon TM, Rifkin C, Klinski C, Lau D et al (1995) 
Iodine-123 metaiodobenzylguanidine scintigraphic assessment of 
the transplanted human heart: evidence for late reinnervation. J 
Am Coll Cardiol 25(4):927–931
 29. Gerson MC, Caldwell JH, Ananthasubramaniam K, Clements IP, 
Henzlova MJ, Amanullah A, Jacobson AF (2011) Influence of 
diabetes mellitus on prognostic utility of imaging of myocardial 
sympathetic innervation in heart failure patients. Circ Cardio-
vasc Imaging 4(2):87–93. https ://doi.org/10.1161/CIRCI MAGIN 
G.110.95478 4
 30. Sobajima M, Ueno H, Onoda H, Kuwahara H, Tanaka S, Ushi-
jima R, Fukuda N, Yokoyama S, Nagura S, Doi T, Yamashita A, 
Fukahara K, Ito H, Kinugawa K (2018) Transcatheter aortic valve 
implantation improves cardiac sympathetic nerve activity on (123)
I-metaiodobenzylguanidine myocardial scintigraphy in severe aor-
tic valve stenosis. Circ J 82(2):579–585. https ://doi.org/10.1253/
circj .cj-17-0817
 31. Yamamoto S, Suzuki H, Sugimura K, Tatebe S, Aoki T, Miura 
M, Yaoita N, Sato H, Kozu K, Ota H, Takanami K, Takase K, 
Shimokawa H (2016) Focal reduction in cardiac (123)I-meta-
iodobenzylguanidine uptake in patients with anderson-fabry 
disease. Circ J 80(12):2550–2551. https ://doi.org/10.1253/circj 
.CJ-16-0690
 32. Imbriaco M, Pellegrino T, Piscopo V, Petretta M, Ponsiglione 
A, Nappi C, Puglia M, Dell’Aversana S, Riccio E, Spinelli L, 
Pisani A, Cuocolo A (2017) Cardiac sympathetic neuronal dam-
age precedes myocardial fibrosis in patients with Anderson-Fabry 
disease. Eur J Nucl Med Mol Imaging 44(13):2266–2273. https ://
doi.org/10.1007/s0025 9-017-3778-1
 33. Yoshita M, Taki J, Yokoyama K, Noguchi-Shinohara M, Matsu-
moto Y, Nakajima K, Yamada M (2006) Value of 123I-MIBG 
radioactivity in the differential diagnosis of DLB from AD. Neu-
rology 66(12):1850–1854. https ://doi.org/10.1212/01.wnl.00002 
19640 .59984 .a7
 34. Simoes MV, Barthel P, Matsunari I, Nekolla SG, Schomig A, 
Schwaiger M, Schmidt G, Bengel FM (2004) Presence of sym-
pathetically denervated but viable myocardium and its electro-
physiologic correlates after early revascularised, acute myocardial 
infarction. Eur Heart J 25(7):551–557. https ://doi.org/10.1016/j.
ehj.2004.02.016
 35. Werner RA, Rischpler C, Onthank D, Lapa C, Robinson S, 
Samnick S, Javadi M, Schwaiger M, Nekolla SG, Higuchi T 
(2015) Retention kinetics of the 18F-labeled sympathetic nerve 
PET tracer LMI1195: comparison with 11C-hydroxyephedrine 
and 123I-MIBG. J Nucl Med 56(9):1429–1433. https ://doi.
org/10.2967/jnume d.115.15849 3
 36. Munch G, Nguyen NT, Nekolla S, Ziegler S, Muzik O, 
Chakraborty P, Wieland DM, Schwaiger M (2000) Evaluation of 
sympathetic nerve terminals with [(11)C]epinephrine and [(11)C]
hydroxyephedrine and positron emission tomography. Circulation 
101(5):516–523
 37. Bravo PE, Lautamaki R, Carter D, Holt DP, Nekolla SG, Dan-
nals RF, Russell SD, Bengel FM (2015) Mechanistic insights into 
sympathetic neuronal regeneration: multitracer molecular imag-
ing of catecholamine handling after cardiac transplantation. Circ 
Cardiovasc Imaging 8(8):e003507. https ://doi.org/10.1161/CIRCI 
MAGIN G.115.00350 7
 38. Fujita W, Matsunari I, Aoki H, Nekolla SG, Kajinami K (2016) 
Prediction of all-cause death using C-11-hydroxyephedrine 
positron emission tomography in Japanese patients with left ven-
tricular dysfunction. Ann Nucl Med 30(7):461–467. https ://doi.
org/10.1007/s1214 9-016-1081-z
 39. Fallavollita JA, Heavey BM, Luisi AJ Jr, Michalek SM, Baldwa 
S, Mashtare TL Jr, Hutson AD, Dekemp RA, Haka MS, Sajjad M, 
Cimato TR, Curtis AB, Cain ME, Canty JM Jr (2014) Regional 
myocardial sympathetic denervation predicts the risk of sudden 
cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 
63(2):141–149. https ://doi.org/10.1016/j.jacc.2013.07.096
 40. Kasai T, Bradley TD (2011) Obstructive sleep apnea and heart 
failure pathophysiologic and therapeutic implications. J Am Coll 
Cardiol 57(2):119–127. https ://doi.org/10.1016/j.jacc.2010.08.627
 41. Hall AB, Ziadi MC, Leech JA, Chen SY, Burwash IG, Renaud J, 
deKemp RA, Haddad H, Mielniczuk LM, Yoshinaga K, Guo A, 
Chen L, Walter O, Garrard L, DaSilva JN, Floras JS, Beanlands 
RSB (2014) Effects of short-term continuous positive airway 
pressure on myocardial sympathetic nerve function and energet-
ics in patients with heart failure and obstructive sleep apnea a 
randomized study. Circulation 130(11):892–901. https ://doi.
org/10.1161/Circu latio naha.113.00589 3
 42. Ducharme J, Goertzen AL, Patterson J, Demeter S (2009) Practi-
cal aspects of 18F-FDG PET when receiving 18F-FDG from a 
distant supplier. J Nucl Med Technol 37(3):164–169. https ://doi.
org/10.2967/jnmt.109.06295 0
 43. Raffel DM, Jung YW, Gildersleeve DL, Sherman PS, Moskwa 
JJ, Tluczek LJ, Chen W (2007) Radiolabeled phenethylguani-
dines: novel imaging agents for cardiac sympathetic neurons and 
adrenergic tumors. J Med Chem 50(9):2078–2088. https ://doi.
org/10.1021/jm061 398y
303Clinical and Translational Imaging (2018) 6:293–303 
1 3
 44. Kobayashi R, Chen X, Werner RA, Lapa C, Javadi MS, Higuchi T 
(2017) New horizons in cardiac innervation imaging: introduction 
of novel (18)F-labeled PET tracers. Eur J Nucl Med Mol Imaging 
44(13):2302–2309. https ://doi.org/10.1007/s0025 9-017-3828-8
 45. Yu M, Bozek J, Lamoy M, Guaraldi M, Silva P, Kagan M, Yala-
manchili P, Onthank D, Mistry M, Lazewatsky J, Broekema M, 
Radeke H, Purohit A, Cdebaca M, Azure M, Cesati R, Casebier D, 
Robinson SP (2011) Evaluation of LMI1195, a novel 18F-labeled 
cardiac neuronal PET imaging agent, in cells and animal models. 
Circ Cardiovasc Imaging 4(4):435–443. https ://doi.org/10.1161/
CIRCI MAGIN G.110.96212 6
 46. Higuchi T, Yousefi BH, Reder S, Beschorner M, Laitinen I, Yu 
M, Robinson S, Wester HJ, Schwaiger M, Nekolla SG (2015) 
Myocardial kinetics of a novel [(18)F]-labeled sympathetic nerve 
PET tracer LMI1195 in the isolated perfused rabbit heart. JACC 
Cardiovasc Imaging 8(10):1229–1231. https ://doi.org/10.1016/j.
jcmg.2014.11.013
 47. Yu M, Bozek J, Lamoy M, Kagan M, Benites P, Onthank D, 
Robinson SP (2012) LMI1195 PET imaging in evaluation of 
regional cardiac sympathetic denervation and its potential role 
in antiarrhythmic drug treatment. Eur J Nucl Med Mol Imaging 
39(12):1910–1919. https ://doi.org/10.1007/s0025 9-012-2204-y
 48. Dae MW, De Marco T, Botvinick EH, O’Connell JW, Hattner RS, 
Huberty JP, Yuen-Green MS (1992) Scintigraphic assessment of 
MIBG uptake in globally denervated human and canine hearts—
implications for clinical studies. J Nucl Med 33(8):1444–1450
 49. Werner RA, Kobayashi R, Javadi MS, Koeck Z, Wakabayashi H, 
Unterecker S, Nakajima K, Lapa C, Menke A, Higuchi T (2018) 
Impact of novel antidepressants on cardiac metaiodobenzylguan-
idine (mIBG) uptake: experimental studies in SK-N-SH cells 
and healthy rabbits. J Nucl Med. https ://doi.org/10.2967/jnume 
d.117.20604 5
 50. Chen X, Werner RA, Lapa C, Nose N, Hirano M, Javadi MS, 
Robinson S, Higuchi T (2018) Subcellular storage and release 
mode of the novel (18)F-labeled sympathetic nerve PET tracer 
LMI1195. EJNMMI Res 8(1):12. https ://doi.org/10.1186/s1355 
0-018-0365-9
 51. Higuchi T, Yousefi BH, Kaiser F, Gartner F, Rischpler C, Reder S, 
Yu M, Robinson S, Schwaiger M, Nekolla SG (2013) Assessment 
of the 18F-labeled PET tracer LMI1195 for imaging norepineph-
rine handling in rat hearts. J Nucl Med 54(7):1142–1146. https ://
doi.org/10.2967/jnume d.112.10423 2
 52. Rischpler C, Fukushima K, Isoda T, Javadi MS, Dannals RF, 
Abraham R, Wahl R, Bengel FM, Higuchi T (2013) Discrepant 
uptake of the radiolabeled norepinephrine analogues hydrox-
yephedrine (HED) and metaiodobenzylguanidine (MIBG) in rat 
hearts. Eur J Nucl Med Mol Imaging 40(7):1077–1083. https ://
doi.org/10.1007/s0025 9-013-2393-z
 53. Sinusas AJ, Lazewatsky J, Brunetti J, Heller G, Srivastava A, Liu 
YH, Sparks R, Puretskiy A, Lin SF, Crane P, Carson RE, Lee 
LV (2014) Biodistribution and radiation dosimetry of LMI1195: 
first-in-human study of a novel 18F-labeled tracer for imaging 
myocardial innervation. J Nucl Med 55(9):1445–1451. https ://
doi.org/10.2967/jnume d.114.14013 7
 54. Zelt J, Ranaud J, Mielniczuk L, Garrard L, Walter O, Guo A, 
deKemp R, Beanlands R (2018) 1312 M-07-Fluorine-18 LMI1195 
positron emission tomography provides accurate measure of car-
diac sympathetic innervation compared to carbon-11 hydrox-
yephedrine. In: Abstract of the 67th Annual Scientifc Session & 
Expo, American College of Cardiology
 55. Jung YW, Jang KS, Gu G, Koeppe RA, Sherman PS, Quesada CA, 
Raffel DM (2017) [(18)F]Fluoro-Hydroxyphenethylguanidines: 
efficient Synthesis and comparison of two structural isomers 
as radiotracers of cardiac sympathetic innervation. ACS Chem 
Neurosci 8(7):1530–1542. https ://doi.org/10.1021/acsch emneu 
ro.7b000 51
 56. Jang KS, Jung YW, Gu G, Koeppe RA, Sherman PS, Quesada CA, 
Raffel DM (2013) 4-[18F]Fluoro-m-hydroxyphenethylguanidine: 
a radiopharmaceutical for quantifying regional cardiac sympa-
thetic nerve density with positron emission tomography. J Med 
Chem 56(18):7312–7323. https ://doi.org/10.1021/jm400 770g
 57. Raffel D, Jung YW, Murthy V, Gu G, Rothley J, Koeppe R, Frey 
K (2016) First-in-human studies of 18F-hydroxyphenethylguani-
dines: pET radiotracers for quantifying cardiac sympathetic nerve 
density. J Nucl Med 57(supplement 2):232
 58. Tinti E, Positano V, Giorgetti A, Marzullo P (2014) Feasibility of 
[(123)I]-meta-iodobenzylguanidine dynamic 3-D kinetic analysis 
in vivo using a CZT ultrafast camera: preliminary results. Eur J 
Nucl Med Mol Imaging 41(1):167–173. https ://doi.org/10.1007/
s0025 9-013-2549-x
 59. Werner RA, Chen X, Hirano M, Nose N, Lapa C, Javadi MS, 
Higuchi T (2018) The impact of ageing on [11C]meta-hydrox-
yephedrine uptake in the rat heart. J Nucl Med 59(supplement 
1):100
